Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542993 · ClinicalTrials.gov registry record · Phase 2
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
A Phase 2 study, sponsored by Swedish Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04542993: Clinical Trial Phase 2 study, sponsored by Swedish Medical Center.
NCT04542993 is a Phase 2 study that was terminated before completion, run by Swedish Medical Center. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04542993, a Phase 2 study, was terminated before completion, sponsored by Swedish Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
Primary Outcome
Viral AUCs normalized to peak viral load and housekeeper genes will be calculated, the AUCs on subjects with complete data will be used as dependent measures in t-tests, regressions and repeated measures mixed ANOVAs to compare viral load reduction between groups
Interventions
- DIETARY_SUPPLEMENT Resveratrol
- DIETARY_SUPPLEMENT Zinc Picolinate
- DIETARY_SUPPLEMENT Zinc Picolinate Placebo
- DIETARY_SUPPLEMENT Resveratrol Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2021-02-05 |
| Phase | Phase 2 |
Why NCT04542993 stopped before completion
NCT04542993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 4 interventions - of which Resveratrol is the first listed.
NCT04542993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04542993 about?
NCT04542993 is a clinical study titled "Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy". Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
What is the current status of trial NCT04542993?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-09-08. Estimated completion is 2021-02-05.
What interventions are being tested in trial NCT04542993?
The interventions under investigation include: Resveratrol (DIETARY_SUPPLEMENT), Zinc Picolinate (DIETARY_SUPPLEMENT), Zinc Picolinate Placebo (DIETARY_SUPPLEMENT), Resveratrol Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04542993?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04542993's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI